ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 92.0 | 52.5 | 57.8 |
| Other income | 0.2 | 0.6 | -2.3 |
| Total income | 92.2 | 53.1 | 55.5 |
| Profit before exceptional items & tax | 1.0 | -3.0 | 0.9 |
| Profit before tax | 1.0 | -3.0 | 0.9 |
| Net profit | 1.8 | -7.1 | 0.7 |
| Operating margin | 1.1% | -5.6% | 1.6% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +157.10% |
|---|---|
| Revenue, year on year | +59.20% |
NSE results filing, NSE: VALIANTLAB. Figures extracted from the filing.
Valiant Laboratories Ltd: key numbers
- Share price
- ₹109.28
- Market cap
- ₹593.5 Cr
- Revenue (annual)
- ₹237.5 Cr
- Net profit (annual)
- ₹-3.27 Cr
- P/E (TTM)
- 36.6×Sector 43.8×
- Promoter holding
- 74.94%+0.00% QoQ
- FII holding
- 0.07%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Valiant Laboratories Ltd
All →Valiant Laboratories Q2 FY27 Results: Net Profit ₹0.4 Cr, Up 100.0% YoY
Valiant Laboratories Ltd reported revenue from operations of ₹116.8 Cr (+152.8% YoY) and net profit of ₹0.4 Cr (+100.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹0.4 Cr · +100.0% YoY
Valiant Laboratories Board Meeting Date
Valiant Laboratories will meet on 2 November 2026 to approve half-year audited results. The trading window stays closed until 4 November.
Valiant Laboratories Other Announcement
Valiant Laboratories Ltd has filed its shareholding pattern for the quarter ended September 30, 2026, in compliance with SEBI regulations.
Valiant Laboratories Annual General Meeting
Valiant Laboratories Limited successfully conducted its 5th Annual General Meeting on September 28, 2026, transacting 18 agenda items including financial statements and various re-appointments.
Valiant Laboratories Acquisition Worth ₹0.7 Cr
Valiant Laboratories approved acquiring up to 1.01% equity in AMPYR Renewable Energy for ₹0.70 Crore. The investment enables captive solar power for its Tarapur plant.
- Value
- ₹0.70 Cr
- Execution
- 12 months from date of board approval
Valiant Laboratories Credit Rating
Valiant Laboratories Limited received a credit rating of IND BBB/Stable/IND A2 from India Ratings and Research for bank loan facilities totaling INR 56 Crore.
- Value
- ₹56.00 Cr